

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Announcement/2024-25

Date: 19.02.2025

**BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001**

**National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla complex
Bandra(E) Mumbai- 400051**

Code No: 531146

Symbol: MEDICAMEQ

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: BSE Scrip Code: 531146; NSE Scrip Code: MEDICAMEQ

Dear Sir/ Ma'am,

Pursuant to provisions of Regulation 30 read with Schedule III Part A para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has entered into a Manufacturing & Supply Agreement with a leading Pharma distributor and marketing Company in US & Europe.

Details that need to be provided as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are attached as Annexure to this letter.

Kindly take the information on record.

Thanking You

**Yours truly,
For Medicamen Biotech Limited**

**Parul Choudhary
Company Secretary
ACS: 44157**

ANNEXURE

Sr. No.	Particulars	Remarks
1	Name of the entity with whom agreement/ JV is signed	The Entity is a leading Pharma distributor and marketing Company in US
2	Area of agreement/JV	Manufacturing & Supply Agreement
3	Domestic/international	International
4	Share exchange ratio / JV ratio	N.A
5	Scope of business operation of agreement / JV	The term of the agreement is of 10 years
6	Details of consideration paid / received in agreement / JV	25% amount as on signing of agreement
7	Significant terms and conditions of agreement / JV in brief	<ul style="list-style-type: none"> Contract manufacturing by the MBL of US based Entity's products according to their technical specification.
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
9	Size of the entity(ies)	The Entity is a leading Pharma distributor and marketing company in US & Europe
10	Rationale and benefit expected	Manufacturing facility of the MBL's USFDA approved Oncology Unit shall be utilized to manufacture the product where it can make use of its manufacturing and process R & D strengths to provide value added custom manufacturing services for various entities.